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July 9, 2012 and were required to stay in the clinical facility from day -1 to study 120 discharge on day 10 or upon early termination. Samatasvir oral suspension or matching 121 placebo was administered under fasting conditions. Cohorts were dosed in parallel 122 without dose escalation. 123
Written informed consent was obtained from all patients. This study was 124 approved by the institutional review boards of the trial centers and conducted in 125 accordance with Good Clinical Practice procedures and the principles of the Declaration 126 of Helsinki, with authorization from the United States Food and Drug Administration. 127
The sample size of this study was calculated primarily based on safety endpoints. 128
With a sample size of 4, 6 or 8 subjects per cohort to receive active samatasvir, the 129 estimated probabilities of observing a particular adverse event (AE) with an expected rate 130 of 20% were 0.59, 0.74 and 0.83, respectively. It was assumed that for this short-term 131 study safety risk would be independent of HCV genotypes or dosing regimen (BID and 132 QD) for the same daily dose. When pooled together across genotypes, the sample size for 133 subjects receiving active samatasvir 50 mg BID or 100 mg QD was 36 leading to an 134 estimated chance of 98% to observe a particular AE with an expected incidence rate of at 135 least 20%. 136 8 plasma for at least six months or liver biopsy within 24 months with histology consistent 141 with chronic HCV infection; HCV genotype 1, 2, 3 or 4; plasma HCV RNA ≥ 142 5 log 10 IU/mL; all patients agreed to use double-barrier birth control (such as a condom 143 plus spermicide) from screening through at least 90 days following the last dose of the 144 study drug. 145
Major exclusion criteria included: pregnancy or breastfeeding; co-infection with 146 HBV or HIV; history or evidence of decompensated liver disease; prior clinical or 147 histological evidence of cirrhosis; alanine aminotransferase or aspartate aminotransferase 148 level > 3.0 × upper limit of normal; history of hepatocellular carcinoma (HCC) or 149 findings suggestive of possible HCC; one or more additional known primary or 150 secondary causes of liver disease, other than HCV; previous antiviral treatment for HCV; 151 current abuse of alcohol or illicit drugs; or other clinically significant diseases that, in the 152 opinion of the investigator, would jeopardize the safety of the patient or impact the 153 validity of the study results. 154
Safety assessments 155
At specific time points throughout the study, blood and urine samples were collected for 156 clinical laboratory analysis including hematology, blood chemistry and urinalysis. Vital 157 signs, 12-lead electrocardiogram (ECG) and physical examinations were performed at 158 predefined time intervals. Safety assessments were based on observed/reported AEs and 159 serious adverse events (SAEs) as well as results from clinical laboratory tests, vital sign 160 measurements, physical examination and ECGs. 
Pharmacokinetics 162
For QD dosing, serial intensive blood samples for PK analysis were collected over 24 163 hours on day 1 and over 120 hours after the last dose on day 3 at the following time 164 points: predose and 0. 5, 1, 2, 3, 4, 6, 8, 12, 16, 20, 24 hours postdose on day 1 and day 3, 165 and 36, 48, 72, 96 and 120 hours post the day-3 dose. For BID dosing, blood samples 166 were obtained predose in the morning (AM) and evening (PM) and at 0.5, 1, 2, 3, 4, 6 and 167 8 hours postdose on day 1 and day 3. In addition, blood samples were obtained at 12, 24, 168 36, 60, 84 and 108 hours post the day-3 PM dose. PK parameters derived from 169 noncompartmental analysis included maximum drug concentration (C max ), time to C max 170 (T max ), predose trough concentration (C τ ) at 24 hours post QD dose or 12 hours post BID 171 dose, area under the plasma concentration-time curve over 24 hours for the total daily 172 dose (AUC 24h ), and observed half-life (t 1/2 ) calculated following the last dose. Plasma 173 concentrations of samatasvir were measured using a validated liquid 174 chromatography/tandem mass spectrometry methodology. All samples were analyzed 175 within the established stability of the analyte. Briefly, internal standard 13 C 5 -15 N-176 samatasvir was added to calibration standards (0.1 to 100 mg/mL), quality control 177 samples (0.3-80 ng/mL) and unknown samples. The mixture was subject to liquid-liquid 178 extraction with a recovery of 87.1% and 96.3% for samatasvir and the internal standard 179 respectively. Chromatography was performed on a ZORBAX 300-SCX column 180 (50 mm × 3 mm; particle size, 5 µm, Agilent Technologies, Santa Clara, CA). Elution 181 was carried out isocratically at a constant flow rate of 1 mL/min with a mobile phase of 182 80:20 (v/v) under positive ion mode using turbo ion spray ionization. This assay has a lower limit of 188 quantitation of 0.1 ng/ml. The intra-and inter-day precisions (coefficient of variation) 189 and accuracies (percent deviation) were from 2.0 to 5.1% and -9.1 to -2.7%, respectively. 190
Antiviral activity 191
Serial blood samples for measuring plasma HCV RNA were obtained during screening, 192 on day -1, during dosing from day 1 to day 3 (day 1 predose and postdose at 4, 8, 12, 16, 193 24, 48 and 72 hours) and during follow-up from day 4 to day 9 or 10 (post day 1 dose at 194 96, 120, 144, 168, 192 and 216 or 240 hours Baseline and demographic characteristics were comparable across dose groups (Table 1) . 231
Antiviral activity 232
Mean changes over time of plasma HCV RNA from baseline are shown in Fig Table 2 . 237 Samatasvir dosed QD or BID for 3 days produced substantial pan-genotypic antiviral 238 activity. The greatest antiviral activity was achieved in subjects having genotype 1b 239 HCV with mean maximum decrease in HCV RNA of 3.0-4.3 log 10 , followed by 3.6-3.9 240 log 10 in genotype 4, 3.2-3.6 log 10 in genotype 1a and 3.2-3.4 log 10 in genotype 3 HCV 241 (see below for antiviral response in subjects with genotype 2 HCV). Maximum decrease 242 in HCV RNA typically occurred upon completion of dosing. Antiviral activity was not 243 observed in subjects receiving placebo. After completion of samatasvir dosing, plasma 244 HCV RNA slowly returned towards baseline but did not attain pre-treatment level within 245 the follow-up period of up to 10 days. 246 Antiviral response to samatasvir in subjects with genotype 2 HCV was 247 determined by a single polymorphism at the NS5A amino acid position 31. Among the 8 248 subjects with genotype 2 HCV who received samatasvir, high antiviral activity with 249 maximum decrease in HCV RNA of 4.0 and 4.1 log 10 was achieved in 2 subjects (Fig. 3,  250 002-006 and 004-019) who had L31 at baseline with no detectable M31 on day 4. In 2 251 subjects who had L31 at baseline but emergence of M31on day 4, robust antiviral activity 252 was retained with maximum decrease in HCV RNA of 2.5 and 3.2 log 10 ( Fig. 3 , 001-147 253 and 001-163). In 1 subject who had an L/M31 mixture at baseline but M31 on day 4, a 254 much reduced antiviral activity (a decrease of 0.8 log 10 ) was obtained (Fig. 3, . 255
Virtually no antiviral activity (0.3-0.5 log 10 reduction) was observed in the 3 subjects 256 with pre-existing M31 who received samatasvir (Fig. 3, 001 -188, 002-017 and 002-016). 257
In contrast, despite all genotype 4 -infected subjects carrying an NS5A M31 at baseline, 258 all responded well to samatasvir treatment (Fig. 2) . Additional details on sequence 259 analyses of other studied HCV genotypes will be reported elsewhere. 260 Pharmacokinetics 261 Fig. 4 depicts the mean day-3 plasma concentration vs. time profiles over the first 24h 262 after dosing, corresponding to the intended QD dosing interval. (Fig. 4) . 276
Predictors of antiviral response 277
Among various baseline characteristics and dose examined using regression analysis, 278 only genotype and dose were significant predictors of viral response (P < 0.0001). 279
Genotype 1b was the most susceptible following by 1a, 3 and 4 which responded 280 comparably to samatasvir; genotype 2 was the least susceptible due to high prevalence of 281 the pre-existing M31 or M/L31 polymorphisms which virtually did not respond to 282 samatasvir. 283
Safety and tolerability 284
Samatasvir was well-tolerated in all subjects. There were no treatment-emergent deaths, 285
SAEs or safety-related discontinuations. AEs were reported at a similar frequency in 286 samatasvir-treated subjects (20 of 48 or 41.7%) and placebo (6 of 12 or 50.0%). As 287 summarized in Table 4 , the most frequent AEs reported were constipation, headache, and 288 nausea. All AEs were mild or moderate in intensity and did not appear to be dose related. 289
There were no apparent dose-related or other patterns of newly occurring or worsening 290 graded hematology, chemistry, or urinalysis abnormalities. There were no clinically 291 significant treatment-emergent changes in vital sign measurements, physical examination 292 findings or ECG parameters. 293
Discussion 294 NS5A replication complex inhibitors are among the most potent DAAs: as a class, these 295 agents at low doses are capable of producing multi-log reductions in plasma HCV RNA 296 within hours of dosing [4, 5] . Other common features of NS5A inhibitors including good 297 safety/tolerability, lack of cross-resistance with other classes of DAAs and once daily 298 dosing make these agents ideal candidates for all oral combination therapy for HCV [3] . 299
While clinical stage NS5A inhibitors all demonstrated antiviral activity against genotype 300 1a/1b HCV as a single agent in their respective proof-of-concept studies, clinical data on 301 activity against other HCV genotypes are scarce [3] . To our knowledge, as monotherapy, 302 samatasvir was the first to demonstrate potent pan-genotypic activity in HCV-infected 303 subjects [5] . In an initial exploratory phase of the current study, single doses of 25-100 304 mg samatasvir afforded a maximum reduction in plasma HCV RNA of up to 3.7 log 10 in 305 subjects with genotype 2 or 3 HCV, similar to genotype 1 [5] . 306
The samatasvir doses for the 3-day proof-of-concept phase were selected based on 307 the single-dose antiviral activity in HCV-infected subjects as well as in vitro antiviral 308 activity against various HCV genotypes [7, 8] . While a single low dose of 1 mg 309 samatasvir was able to produce over 3 log 10 reduction in plasma HCV RNA, dose-310 response analyses using data from the single-dose phase suggested that doses of 25 mg 311 and above might achieve more consistent antiviral effect [5] . Therefore, doses of 25-100 312 mg/day were selected for the 3-day dosing in subjects with genotype 1 HCV. Samatasvir 313 exhibits potent and slightly differential in vitro antiviral activity against the more 314 sensitive genotype 1a/1b and genotype 4a replicons (EC 50 : 2.0-6.2 pM) and the less 315 sensitive genotype 2 (EC 50 =24 pM) and genotype 3 (EC 50 =17 pM) [7, 8] . These in vitro 316 data in conjunction with the single-dose anti-HCV activity observed in patients with 317 genotype 2 or 3 in part 1 of the study favored the 100 mg/day dose in subjects with these 318 genotypes in the 3-day dosing phase. 319
Results from the current 3-day proof-of-concept part of the study confirmed the 320 pan-genotypic antiviral activity observed during the exploratory single-dose phase, but 321 were comparable with those observed in genotype 1 subjects with a mean maximum 328 reduction of 3.2-3.9 log 10 . A similar degree of viral suppression was also achieved in 329 subjects with genotype 2 HCV who had no pre-existing M31 or L/M31 polymorphism. 330
Pre-existing M31 polymorphism in genotype 2 subjects predicts lack of virologic 331 response, and emerging M31 is associated with reduced antiviral activity to samatasvir 332
monotherapy. 333
While all current clinical-stage NS5A inhibitors are able to induce substantial 334 early viral response, this class of HCV DAA is, however, prone to rapidly select viral 335 variants as a single agent [3] . Indeed, viruses in the current study underwent treatment-336 emergent selection of NS5A variants associated with in vitro resistance (primarily at 337 positions 93, 28, 30 and 31, details to be presented elsewhere) although no subject 338 experienced an on-treatment rebound defined as a 0.5 log 10 increase above nadir with 339 samatasvir as a single agent dosed for 3 days. During a 14-day monotherapy with 340 daclatasvir, viral rebounds occurred early (generally before 7 days) and were associated 341 with emergence of resistant variants [4] . The lack of viral breakthrough while on 342 samatasvir in the current study contrasts with the observed rapid selection of resistance-343 associated variants. These conflicting observations might be a consequence of the short 344 duration of treatment, i.e., the treatment-selected variants may not have had sufficient 345 time to rebound from their suppressed levels in the presence of drug. The low barrier to 346 resistance with NS5A inhibitors as monotherapy appears to have little clinical relevance 347 when these drugs are used in combination with other classes of DAAs including 348 nucleotide, non-nucleotide NS5B and protease inhibitors. In fact, the majority of the best 349 sustained virologic response data (>90%) obtained to date are from experimental all-oral 350 combination regimens involving NS5A inhibitors [18] [19] [20] [21] . During this short-term proof-of-concept study, samatasvir was well tolerated with 371 no dose-related safety findings. While its safety and tolerability will need to be further 372 defined in longer-term/larger trials, clinical data to date have shown satisfactory safety 373 profiles for NS5A inhibitors as a class [3] . 374
In conclusion, at the tested doses of 25-100 mg/day for 3 days, samatasvir was 375 safe and demonstrated substantial pan-genotypic antiviral activity in treatment-naïve 376 patients infected with genotype 1, 2, 3 or 4 HCV. The pharmacokinetic and antiviral 377 profiles of samatasvir make it a desirable component in all-oral DAA combination 378 regimens. A phase II study of once-daily samatasvir in combination with simeprevir in 379 treatment-naïve patients with genotype 1b or 4 HCV is ongoing. 380
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